238 related articles for article (PubMed ID: 37898609)
41. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.
Brotin E; Meryet-Figuière M; Simonin K; Duval RE; Villedieu M; Leroy-Dudal J; Saison-Behmoaras E; Gauduchon P; Denoyelle C; Poulain L
Int J Cancer; 2010 Feb; 126(4):885-95. PubMed ID: 19634140
[TBL] [Abstract][Full Text] [Related]
42. Functional and biological analysis of Bcl-xL expression in human osteosarcoma.
Wang ZX; Yang JS; Pan X; Wang JR; Li J; Yin YM; De W
Bone; 2010 Aug; 47(2):445-54. PubMed ID: 20580954
[TBL] [Abstract][Full Text] [Related]
43. Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-X
Yao W; Bai L; Wang S; Zhai Y; Sun SY
Neoplasia; 2022 Jul; 29():100798. PubMed ID: 35462114
[TBL] [Abstract][Full Text] [Related]
44. Trichonomas vaginalis metalloproteinase induces apoptosis of SiHa cells through disrupting the Mcl-1/Bim and Bcl-xL/Bim complexes.
Quan JH; Kang BH; Cha GH; Zhou W; Koh YB; Yang JB; Yoo HJ; Lee MA; Ryu JS; Noh HT; Kwon J; Lee YH
PLoS One; 2014; 9(10):e110659. PubMed ID: 25343522
[TBL] [Abstract][Full Text] [Related]
45. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
46. Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro.
Koehler BC; Scherr AL; Lorenz S; Urbanik T; Kautz N; Elssner C; Welte S; Bermejo JL; Jäger D; Schulze-Bergkamen H
PLoS One; 2013; 8(10):e76446. PubMed ID: 24098503
[TBL] [Abstract][Full Text] [Related]
47. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
Modi V; Sankararamakrishnan R
J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
[TBL] [Abstract][Full Text] [Related]
48. Molecular dynamic simulations on an inhibitor of anti-apoptotic Bcl-2 proteins for insights into its interaction mechanism for anti-cancer activity.
Anantram A; Kundaikar H; Degani M; Prabhu A
J Biomol Struct Dyn; 2019 Aug; 37(12):3109-3121. PubMed ID: 30526410
[TBL] [Abstract][Full Text] [Related]
49. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
50. Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation.
Opydo M; Mlyczyńska A; Mlyczyńska E; Rak A; Kolaczkowska E
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108344
[TBL] [Abstract][Full Text] [Related]
51. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
[TBL] [Abstract][Full Text] [Related]
52. Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.
Richard DJ; Lena R; Bannister T; Blake N; Pierceall WE; Carlson NE; Keller CE; Koenig M; He Y; Minond D; Mishra J; Cameron M; Spicer T; Hodder P; Cardone MH
Bioorg Med Chem; 2013 Nov; 21(21):6642-9. PubMed ID: 23993674
[TBL] [Abstract][Full Text] [Related]
53. Bcl-2 family inhibitors sensitize human cancer models to therapy.
Valentini E; Di Martile M; Brignone M; Di Caprio M; Manni I; Chiappa M; Sergio I; Chiacchiarini M; Bazzichetto C; Conciatori F; D'Aguanno S; D'Angelo C; Ragno R; Russillo M; Colotti G; Marchesi F; Bellone ML; Dal Piaz F; Felli MP; Damia G; Del Bufalo D
Cell Death Dis; 2023 Jul; 14(7):441. PubMed ID: 37460459
[TBL] [Abstract][Full Text] [Related]
54. What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?
Brinkmann K; Ng AP; de Graaf CA; Strasser A
Cell Death Differ; 2022 Jun; 29(6):1079-1093. PubMed ID: 35388168
[TBL] [Abstract][Full Text] [Related]
55. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.
Peddaboina C; Jupiter D; Fletcher S; Yap JL; Rai A; Tobin RP; Jiang W; Rascoe P; Rogers MK; Smythe WR; Cao X
BMC Cancer; 2012 Nov; 12():541. PubMed ID: 23171055
[TBL] [Abstract][Full Text] [Related]
56. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
57. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
[TBL] [Abstract][Full Text] [Related]
58. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
[TBL] [Abstract][Full Text] [Related]
59. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
[TBL] [Abstract][Full Text] [Related]
60. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer.
Scherr AL; Mock A; Gdynia G; Schmitt N; Heilig CE; Korell F; Rhadakrishnan P; Hoffmeister P; Metzeler KH; Schulze-Osthoff K; Illert AL; Boerries M; Trojan J; Waidmann O; Falkenhorst J; Siveke J; Jost PJ; Bitzer M; Malek NP; Vecchione L; Jelas I; Brors B; Glimm H; Stenzinger A; Grekova SP; Gehrig T; Schulze-Bergkamen H; Jäger D; Schirmacher P; Heikenwalder M; Goeppert B; Schneider M; Fröhling S; Köhler BC
Cell Death Dis; 2020 Oct; 11(10):875. PubMed ID: 33070156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
